Available Now - Resoundant Spring Newsletter

Get caught up on all-things-MRE with our spring newsletter.

Renaming NAFLD: The Importance and Implications of the Transition to MASLD

Resoundant Appoints Joel Felmlee, PhD, as Chief Operating Officer

Resoundant ships 2022nd MRE unit worldwide

Exploring the use of MRE to guide treatment and predict outcomes in patients with NAFLD